Background: and Purpose: This clinical practice guideline provides evidence-based recommendations for treatment of dementia, focusing on cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists for Alzheimer’s disease (AD) and other types of dementia. Methods: Using the Population, Intervention, Comparison, Outcomes (PICO) framework, we developed key clinical questions and conducted systematic literature reviews. A multidisciplinary panel of experts, organized by the Korean Dementia Association, evaluated randomized controlled trials and observational studies. Recommendations were graded for evidence quality and strength using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Results: Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson’s disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. Both drug classes showed favorable safety profiles with manageable side effects. Conclusions This guideline offers standardized, evidence-based pharmacologic recommendations for dementia management, with specific guidance on cholinesterase inhibitors and NMDA receptor antagonists. It aims to support clinical decision-making and improve patient outcomes in dementia care. Further updates will address emerging treatments, including amyloid-targeting therapies, to reflect advances in dementia management.

Background: and Purpose: This clinical practice guideline provides evidence-based recommendations for treatment of dementia, focusing on cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists for Alzheimer’s disease (AD) and other types of dementia. Methods: Using the Population, Intervention, Comparison, Outcomes (PICO) framework, we developed key clinical questions and conducted systematic literature reviews. A multidisciplinary panel of experts, organized by the Korean Dementia Association, evaluated randomized controlled trials and observational studies. Recommendations were graded for evidence quality and strength using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Results: Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson’s disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. Both drug classes showed favorable safety profiles with manageable side effects. Conclusions This guideline offers standardized, evidence-based pharmacologic recommendations for dementia management, with specific guidance on cholinesterase inhibitors and NMDA receptor antagonists. It aims to support clinical decision-making and improve patient outcomes in dementia care. Further updates will address emerging treatments, including amyloid-targeting therapies, to reflect advances in dementia management.

Background: and Purpose: This clinical practice guideline provides evidence-based recommendations for treatment of dementia, focusing on cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists for Alzheimer’s disease (AD) and other types of dementia. Methods: Using the Population, Intervention, Comparison, Outcomes (PICO) framework, we developed key clinical questions and conducted systematic literature reviews. A multidisciplinary panel of experts, organized by the Korean Dementia Association, evaluated randomized controlled trials and observational studies. Recommendations were graded for evidence quality and strength using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Results: Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson’s disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. Both drug classes showed favorable safety profiles with manageable side effects. Conclusions This guideline offers standardized, evidence-based pharmacologic recommendations for dementia management, with specific guidance on cholinesterase inhibitors and NMDA receptor antagonists. It aims to support clinical decision-making and improve patient outcomes in dementia care. Further updates will address emerging treatments, including amyloid-targeting therapies, to reflect advances in dementia management.

Background: and Purpose: This clinical practice guideline provides evidence-based recommendations for treatment of dementia, focusing on cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists for Alzheimer’s disease (AD) and other types of dementia. Methods: Using the Population, Intervention, Comparison, Outcomes (PICO) framework, we developed key clinical questions and conducted systematic literature reviews. A multidisciplinary panel of experts, organized by the Korean Dementia Association, evaluated randomized controlled trials and observational studies. Recommendations were graded for evidence quality and strength using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Results: Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson’s disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. Both drug classes showed favorable safety profiles with manageable side effects. Conclusions This guideline offers standardized, evidence-based pharmacologic recommendations for dementia management, with specific guidance on cholinesterase inhibitors and NMDA receptor antagonists. It aims to support clinical decision-making and improve patient outcomes in dementia care. Further updates will address emerging treatments, including amyloid-targeting therapies, to reflect advances in dementia management.

Purpose: This study aimed to assess the antimicrobial efficacy of an 810-nm infrared diode laser with indocyanine green (ICG) against Staphylococcus aureus on sandblasted, large grit, and acid-etched (SLA) titanium surfaces, comparing its effectiveness with alternative chemical decontamination modalities. Materials and Methods: Biofilms of S. aureus ATCC 25923 were culturedon SLA titanium disks for 48 hours. The biofilms were divided into five treatment groups: control, chlorhexidine gluconate (CHX), tetracycline (TC), ICG, and 810-nm infrared diode laser with ICG (ICG-PDT). After treatment, colony-forming units were quantified to assess surviving bacteria, and viability was confirmed through confocal laser-scanning microscope (CLSM) imaging. Results: All treated groups exhibited a statistically significant reduction in S. aureus (P < 0.05), with notable efficacy in the CHX, TC, and ICG-PDT groups (P < 0.01). While no statistical difference was observed between TC and CHX, the ICG-PDT group demonstrated superior bacterial reduction. CLSM images revealed a higher proportion of dead bacteria stained in red within the ICG-PDT groups. Conclusion Within the limitations, ICG-PDT effectively reduced S. aureus biofilms on SLA titanium surfaces. Further investigations into alternative decontamination methods and the clinical impact of ICG-PDT on peri-implant diseases are warranted.

Purpose: Staphylococcus aureus can attach to extracellular matrix components and plasma proteins deposited on biomaterial surfaces, ultimately forming biofilms. Therefore, managing S. aureus is recommended for preventing and treating peri-implant diseases. This study aimed to evaluate the biofilm-forming ability of S. aureus on zirconia surfaces and to assess the efficacy of photodynamic therapy (PDT) in reducing these biofilms. Materials and Methods: Biofilm growth analysis showed optimal formation at 48 hours. Therefore, S. aureus ATCC 25923 was inoculated onto a sterilized zirconia disk and cultivated for 48 hours to form the biofilm. Thereafter, the biofilms were treated with phosphate-buffered saline (PBS; control), chlorhexidine (CHX), tetracycline (TC),toluidine blue O (TBO), cold diode laser (laser), or PDT (TBO + laser), with each group consisting of seven disks. The bacterial loadwas quantified using colony-forming unit (CFU) counts, and biofilm viability was evaluated using confocal laser scanning microscopy (CLSM). Results: Significant reductions in bacterial counts were observed in the CHX (95.3%), TC (95.0%), and PDT (93.8%) groups compared to the control (P < 0.001). CLSM revealed a greater number of dead bacteria in the CHX, TC and PDT groups compared to that in other groups. Conclusion Within its limitations, this study demonstrated that S. aureus can form biofilms on zirconia surfaces. PDT showed similar efficacy to conventional antimicrobial treatments such as CHX and TC for reducing S. aureus biofilms.zirconia

Purpose: This study aimed to assess the antimicrobial efficacy of an 810-nm infrared diode laser with indocyanine green (ICG) against Staphylococcus aureus on sandblasted, large grit, and acid-etched (SLA) titanium surfaces, comparing its effectiveness with alternative chemical decontamination modalities. Materials and Methods: Biofilms of S. aureus ATCC 25923 were culturedon SLA titanium disks for 48 hours. The biofilms were divided into five treatment groups: control, chlorhexidine gluconate (CHX), tetracycline (TC), ICG, and 810-nm infrared diode laser with ICG (ICG-PDT). After treatment, colony-forming units were quantified to assess surviving bacteria, and viability was confirmed through confocal laser-scanning microscope (CLSM) imaging. Results: All treated groups exhibited a statistically significant reduction in S. aureus (P < 0.05), with notable efficacy in the CHX, TC, and ICG-PDT groups (P < 0.01). While no statistical difference was observed between TC and CHX, the ICG-PDT group demonstrated superior bacterial reduction. CLSM images revealed a higher proportion of dead bacteria stained in red within the ICG-PDT groups. Conclusion Within the limitations, ICG-PDT effectively reduced S. aureus biofilms on SLA titanium surfaces. Further investigations into alternative decontamination methods and the clinical impact of ICG-PDT on peri-implant diseases are warranted.

Purpose: Staphylococcus aureus can attach to extracellular matrix components and plasma proteins deposited on biomaterial surfaces, ultimately forming biofilms. Therefore, managing S. aureus is recommended for preventing and treating peri-implant diseases. This study aimed to evaluate the biofilm-forming ability of S. aureus on zirconia surfaces and to assess the efficacy of photodynamic therapy (PDT) in reducing these biofilms. Materials and Methods: Biofilm growth analysis showed optimal formation at 48 hours. Therefore, S. aureus ATCC 25923 was inoculated onto a sterilized zirconia disk and cultivated for 48 hours to form the biofilm. Thereafter, the biofilms were treated with phosphate-buffered saline (PBS; control), chlorhexidine (CHX), tetracycline (TC),toluidine blue O (TBO), cold diode laser (laser), or PDT (TBO + laser), with each group consisting of seven disks. The bacterial loadwas quantified using colony-forming unit (CFU) counts, and biofilm viability was evaluated using confocal laser scanning microscopy (CLSM). Results: Significant reductions in bacterial counts were observed in the CHX (95.3%), TC (95.0%), and PDT (93.8%) groups compared to the control (P < 0.001). CLSM revealed a greater number of dead bacteria in the CHX, TC and PDT groups compared to that in other groups. Conclusion Within its limitations, this study demonstrated that S. aureus can form biofilms on zirconia surfaces. PDT showed similar efficacy to conventional antimicrobial treatments such as CHX and TC for reducing S. aureus biofilms.zirconia

Purpose: This study aimed to assess the antimicrobial efficacy of an 810-nm infrared diode laser with indocyanine green (ICG) against Staphylococcus aureus on sandblasted, large grit, and acid-etched (SLA) titanium surfaces, comparing its effectiveness with alternative chemical decontamination modalities. Materials and Methods: Biofilms of S. aureus ATCC 25923 were culturedon SLA titanium disks for 48 hours. The biofilms were divided into five treatment groups: control, chlorhexidine gluconate (CHX), tetracycline (TC), ICG, and 810-nm infrared diode laser with ICG (ICG-PDT). After treatment, colony-forming units were quantified to assess surviving bacteria, and viability was confirmed through confocal laser-scanning microscope (CLSM) imaging. Results: All treated groups exhibited a statistically significant reduction in S. aureus (P < 0.05), with notable efficacy in the CHX, TC, and ICG-PDT groups (P < 0.01). While no statistical difference was observed between TC and CHX, the ICG-PDT group demonstrated superior bacterial reduction. CLSM images revealed a higher proportion of dead bacteria stained in red within the ICG-PDT groups. Conclusion Within the limitations, ICG-PDT effectively reduced S. aureus biofilms on SLA titanium surfaces. Further investigations into alternative decontamination methods and the clinical impact of ICG-PDT on peri-implant diseases are warranted.

Purpose: Staphylococcus aureus can attach to extracellular matrix components and plasma proteins deposited on biomaterial surfaces, ultimately forming biofilms. Therefore, managing S. aureus is recommended for preventing and treating peri-implant diseases. This study aimed to evaluate the biofilm-forming ability of S. aureus on zirconia surfaces and to assess the efficacy of photodynamic therapy (PDT) in reducing these biofilms. Materials and Methods: Biofilm growth analysis showed optimal formation at 48 hours. Therefore, S. aureus ATCC 25923 was inoculated onto a sterilized zirconia disk and cultivated for 48 hours to form the biofilm. Thereafter, the biofilms were treated with phosphate-buffered saline (PBS; control), chlorhexidine (CHX), tetracycline (TC),toluidine blue O (TBO), cold diode laser (laser), or PDT (TBO + laser), with each group consisting of seven disks. The bacterial loadwas quantified using colony-forming unit (CFU) counts, and biofilm viability was evaluated using confocal laser scanning microscopy (CLSM). Results: Significant reductions in bacterial counts were observed in the CHX (95.3%), TC (95.0%), and PDT (93.8%) groups compared to the control (P < 0.001). CLSM revealed a greater number of dead bacteria in the CHX, TC and PDT groups compared to that in other groups. Conclusion Within its limitations, this study demonstrated that S. aureus can form biofilms on zirconia surfaces. PDT showed similar efficacy to conventional antimicrobial treatments such as CHX and TC for reducing S. aureus biofilms.zirconia